Clinicn Investigator, Full Prf
Cancer Center,
Mass General Research Institute
|
Professor of Medicine
Harvard Medical School
|
Associate Physician
Medicine-Hematology/Oncology,
Massachusetts General Hospital
|
antineoplastic agents; benzenesulfonates; cancer clinical trials; carcinoma renal cell; melanoma; protein kinase inhibitors; proto-oncogene proteins b-raf; pyridines; skin neoplasms
Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer. In this context he focused on the development of response and predictive biomarkers to define the mechanisms of action and resistance of novel therapies, as well as to identify the optimal target population.
